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ABSTRACT
Background: Cardiovascular disease is the leading cause of death in the United States.
There were over 18 million people diagnosed with diabetes in 2002. These disease
processes together combine for significant health burden on society (American Diabetes
Association, 2008). The purpose of the study was to describe the relationship between
select demographics, and clinical characteristics to determine risk factors for
cardiovascular disease in a diabetic population.
Methods: A retrospective descriptive study was conducted using a diabetic registry
database containing patients diagnosed with diabetes from January 1, 2011 to December
31,2012. Study variables included age, gender, socio-economic status, glycosylated
hemoglobin levels (HgbAlc), micro-albumin levels, and low density lipoprotein levels
(LDL). Descriptive and inferential statistics were conducted using SPSS Windows
version 22.
Results: For the total cases (N=292) age ranging 35 years to 97 years, 57% female, the
analysis revealed only one independent variable, gender, demonstrated a relationship with
the dependent variable, LDL (r =.138; p =>0.009). For the regression analysis, combined
variability of the independent variables (age, gender, socio-economic status, HgbAlc,
and micro-albumin) accounted for only three percent variance in the dependent variable
(p =0.134). The overall model was not a good fit to the sample data.
Conclusions: The diabetic registry used for this study was designed to meet regulatory
and accreditation requirements and as such had limited categories of data. The
practicality of using a database for research has benefits, but can also impose significant

limitations. In this study the data categories were limited, possibly accounting for the lack
of model fit. However, the findings did indicate a premise for future research using a
diabetic registry if changes could be made to collect more categories of data such that the
findings could provide full characterization of the sample and generalizability of the
findings.
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Chapter One
INTRODUCTION
Overview o f the Problem
Cardiovascular disease (CVD) is a significant health problem in the United States.
It affects more than 70 million people and accounts for approximately 40% of all deaths
in the United States (Pal, 2006). In 2005 the estimated cost o f care for CVD was $393.5
billion (Pal, 2006; Veazie et al., 2005). Heart disease was the leading cause of death in
2010, cerebrovascular disease ranked 4th (Murphy, 2013). Physiologic risk factors for
CVD include elevated low density lipoprotein levels (LDL), blood pressure, obesity and
diabetes. Behavioral risk factors include diet, exercise and tobacco abuse (Cooper et al.,
2000; Pearson et al., 2002). Elevated LDL levels are an independent risk factor for CVD
and lowering levels o f LDL has significantly reduced the risk of CVD (Pearson et al.,
2002). Diabetes is also an independent risk factor for CVD. There is a strong association
between CVD and diabetes. Individuals with diabetes have two to four times greater heart
disease death rates and two to four times greater death rates from stroke then non-diabetic
individuals with CVD (Garg & Bakris, 2002; Grundy et al., 1999; Kvan, Pettersen,
Sandvik, Reikvam, & Investigators, 2007; Stem, 1995). Because those individuals with
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CVD and diabetes have a higher mortality rate when compared to non-diabetic
individuals, studying the contributors to CVD in individuals with diabetes is an important
research topic (Liu et al., 2005). Therefore, an investigation determining associations
between specific bio-markers for CVD and diabetes, in a diabetic population, could be
beneficial in the long term for improving patient care.

Background o f the Problem
Cardiovascular Disease
Cardiovascular disease (CVD) is a disease process that occurs in the arteries and
veins of the vascular system and heart. This disease occurs most commonly from build
up of plaque in vessel walls and endothelial inflammation (Pearson et al., 2002).
Structural problems from birth defects, genetic predisposition, and history o f illicit drug
abuse are also contributing factors in the development of CVD as well. Regardless of
underlying pathology, this disease process causes heart attacks, heart failure, strokes,
aneurysms, and decreased peripheral arterial blood flow that can lead to amputations of
limbs. The morbidity and mortality of CVD increases two to four fold in individuals with
diabetes compared to individuals without diabetes making diabetes a significant risk
factor in developing CVD (Garg & Bakris, 2002; Kvan et al., 2007).
Diabetes
Diabetes mellitus (DM) is a metabolic disorder characterized by elevated
circulating glucose levels in the blood caused by either lack of production o f insulin by
the pancreas or resistance o f insulin at the cellular level. Either the loss of production of
insulin or resistance of insulin at the cellular level, are the determining factors when
making the diagnosis of diabetes. Diabetes mellitus type 1 (DM 1) is characterized by the
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loss of insulin producing cells of the pancreas, the islets of Langerhans. The underlying
pathology of DM 1 is either immune-mediated, idiopathic or traumatic and accounts for
approximately 10% of all cases of diabetes (Lambert & Bingley, 2002). Diabetes mellitus
type 2 (DM 2) is far more prevalent and accounts for approximately 90% of all cases of
diabetes
Diabetes mellitus 2 is characterized by two defects: insulin resistance and
impaired insulin secretion. This disrupts the communication o f insulin target tissues and
the beta cells. The result in Type 2 diabetes is characterized by diminished peripheral
insulin action, increased hepatic glucose production and impaired insulin secretion.
Unlike DM 1 there are known risk factors in the development of DM 2. Obesity is
considered to be greatest risk factor (Scheen, 2003). More likely, it is the combined
effects of obesity, genetics, and poor diet that culminate in the diagnosis of DM 2 (Stem,
1995).
Cardiovascular disease (CVD) is highly correlated with both types of diabetes. It
is interesting to note that elevated LDL levels in individuals with diabetes and individuals
without diabetes are predictive of an increase in mortality from CVD in both populations.
However, the diabetic population has a much higher mortality rate from CVD than
individuals without diabetes (Bucala et al., 1994; Liu et al., 2005; Stem, 1995). There is a
third disease process to consider when discussing CVD and diabetes. Renal disease is
also considered to have a significant relationship with CVD and diabetes. However, it is
not known if it precedes the other conditions or occurs as a result of CVD and DM
(Bucala et al., 1994; Lane, 2004; Stehouwer & Smulders, 2006).
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Renal Disease
Renal disease can be described as either acute kidney injury (AKI) or as chronic
kidney disease (CKD). The AKI disease process can result from a variety o f physiologic
insults that include ischemic injury, cardiovascular surgery, sepsis, and radiocontrast
administration. It occurs in approximately 5% of hospitalized patients. However, the
occurrence increases to 15-30% for those considered high risk patients. The high risk
patients are those who have had cardiovascular surgery and those patients that are septic.
It is interesting to note that this high risk group is more likely to develop CKD. It is
believed this is due to the improved mortality in this population, thus making this
population at risk for advancing to CKD (Singh, Ricksten, Bragadottir, Redfors, &
Nordquist, 2013). The development of CKD is more insidious and risk factors include not
only AKI but also hypertension and diabetes.
Chronic Kidney Disease (CKD) is staged based on renal function values that
include glomerular filtration rate (GFR) and albuminuria. As GFR decreases, urine
protein levels increase. The more inverse this relationship becomes determines the stage
o f CKD with stage 1 being mild and stage 5 being end stage renal disease (ESRD). While
the exact mechanism that causes low GFR and an increase in urine albumin levels is not
known, it is believed to be related to renal oxygenation and hemodynamics. Specifically,
the impairment of oxygen balance that causes hypoxia and cellular starvation induce
disturbances in extracellular matrix production, deposition of collagen and fibrosis (Singh
et al., 2013). Renal oxygenation and hemodynamic problems are found in individuals
with hypertension and diabetes and are highly correlated with CVD. It is this association
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that makes a renal marker such as micro-albumin level useful in determining the
relationship between a known CVD marker such as LDL (Garg & Bakris, 2002).

Problem Statement
Cardiovascular disease (CVD) is the leading cause of mortality in the United
States (Murphy, 2013). It is responsible for approximately 40 % of all deaths in the
United States. This exceeds the next five leading causes of death combined (Veazie et al.,
2005). Diagnosing and treating CVD in the United States is estimated to cost billions
annually (Pal, 2006). There is an increase in mortality for those with CVD who also have
diagnosis of DM (Grundy et al., 1999; Stem, 1995). Diabetes is also a significant health
problem in the United States with more than 18 million diagnosed in 2002 (Engelgau et
al., 2004) and costing more than $174 billion in 2007 (American Diabetes Association,
2008). These disease processes together combine for significant health and economic
burden on society (American Diabetes Association, 2008). Using LDL as a bio-marker
for coronary artery disease (CAD) has been established (Holvoet et al., 2001). It is also
known that lower LDL levels equate to less risk of developing CVD (Pearson et al.,
2002). The gap in the research that there has yet to be an identified relationship of micro
albumin, HgbAlc and LDL in a diabetic population (Hinzmann, Schlaeger, & Tran,
2012). Therefore, a study to investigate the relationships of these variables using a
diabetic population could be beneficial in determining CVD risk factors in this
population.

Purpose of Study
The purpose of this retrospective descriptive data-based study will be to
investigate the relationship between HgbAlc, micro-albumin levels, select demographics
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(age, gender, socio-economic status), and low density lipoprotein levels. The cases for
this study will be drawn from a clinical database. To ensure that all cases in the database
have a diagnosis of diabetes the sample will be chosen from a diabetic registry data bank.
This study will use data to determine if the independent variables of age, gender, socio
economic status, HgbAlc and micro-albumin have a significant relationship with the
dependent variable, LDL.

Conceptual Framework
The variables for this study can be categorized as follows: demographics, clinical
characteristics and a primary clinical marker for CVD risk. The demographic variables
will include age, gender and socio-economic status. The clinical characteristic variables
will include HgbAlc, and micro-albumin. The LDL variable will be the outcome variable
representing a primary clinical marker for CVD. See Figure 1.

Study
Variables

Demographics

+

Age

Clinical
Maiker
For CV risk

Clinical
Characteristics

HbgAlc

Gender
Measurements

LDL
SocioEconomic
Status
Microalbumi

Figure 1: Conceptual Framework
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Study Design
This study will consist of a retrospective descriptive correlation design using de
identified data. The data are housed within a California health care organization’s
diabetic registry and will span from January 1, 2011 to December 31,2012. All de
identified data that will be abstracted for investigation will have at least one numerical
entry for each of the following: HgbAlc, micro-albumin, and LDL. Each case will
include select demographics specifically age, gender and socio-economic status. No cases
will have missing data.

Study Aims
Aiml: To describe HgbAlc levels, micro-albumin levels, LDL levels and select
demographics (age, gender, socio-economic status).
Aim 2: To determine if there is a relationship between LDL levels and HgbAlc
levels.
Aim 3: To determine if there is a relationship between LDL levels and micro
albumin levels.
Aim 4: To determine if there is a relationship between LDL levels and select case
demographics (age, gender, socio-economic status).
Aim 5: To determine the degree o f variability in LDL levels accounted for by
HgbAlc levels, micro-albumin levels and select case demographics (age,
gender, socio-economic status).

Implications for Nursing
Cardiovascular disease (CVD) is a significant health problem and nurses are vital
in assisting patients in improving their cardiovascular health (Veazie et al., 2005). This
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study will determine if there are relationships among select variables. This project will
determine the relationship between select demographics, laboratory tests and LDL as a
biomarker for CVD in a diabetic population. The findings from this study can be used by
nurses to target clinical indicators for improvement, ultimately improving the
cardiovascular health in this patient population.

Conclusion
This chapter presented a discussion and overview of the issues related to
cardiovascular disease. The discussion provided background information on
cardiovascular disease, diabetes and renal disease. The patient population for this study
was determined. Also a framework was provided that conceptualizes the relationship
between the variables for this study. Lastly, the significance of the study was discussed.
The review of the literature, in Chapter Two, will provide further insight into the
necessity of this study.

Chapter Two
REVIEW OF THE LITERATURE
Introduction
This chapter will review the literature that is relevant to the investigation of the
relationships between the variables in this study. The conceptual framework for this study
will describe the predicted relationship among the variables. There will be a discussion of
the literature that supports the necessity of this study. This discussion will include a
review of relevant research in cardiovascular disease and the use of glycosylated
hemoglobin levels, micro-albumin levels and select demographics (age, gender,
socioeconomic status) in cardiovascular research.

Conceptual Framework
The variables for this study can be categorized as follows, demographics, clinical
characteristics and a primary clinical marker for cardiovascular risk. The demographic
variables will include age, gender and socio-economic status. The clinical characteristic
variables will include glycosylated hemoglobin levels (HgbAlc), and micro-albumin.
The low density lipoprotein (LDL) variable will be the outcome variable representing a
primary clinical marker for cardiovascular disease (CVD). See figure 1.
9
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Cardiovascular disease:
Cardiovascular disease (CVD) has been the leading cause of death worldwide
since 1990 (Veazie et al., 2005). However, CVD was identified as a significant health
risk prior to 1990. The National Heart Institute (NHI) noticed there was an increase in
death from CVD in the early 1900s. In an ambitious attempt to learn more about CVD,
the National Heart, Lung, and Blood Institute (NHLBI) partnered with Boston University
to develop the Framingham Heart Study (FHS). The objective of this population-based
prospective family cohort study was to identify common risk factors in a population that
had no obvious symptoms of CVD or history of stroke or a heart attack at the time of
enrollment. The population for the study was recruited from Framingham, Massachusetts
and involved over 5,000 men and women. Data collected every two years included
medical and lifestyle history, laboratory tests and physical examinations. From this
original cohort it was learned that smoking, low levels of activity, high cholesterol level,
high blood pressure, electrocardiogram abnormalities including atrial fibrillation, were
associated with increased risk of heart disease and strokes ("Framingham Heart Study,").
In 1971, a second generation cohort was enrolled. This cohort included adult children of
the original cohorts and was known as the Offspring cohort. The Third Generation
cohort, enrolled in 2002, is the grandchildren o f the Original cohort.
In her 2010 article, Caroline S. Fox describes the current state of knowledge
obtained from the Framingham Heart Study. She evaluates diabetes as a risk factor for
CVD and demonstrated an increased association of diabetes and CVD over the years of
the FHS. Lastly, she offered suggestions for future research.
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Fox, (2010), reported that early on in the FHS that diabetes was recognized as a
risk factor for CVD and was associated with a 2-4 fold increased risk of myocardial
infarction, peripheral arterial disease, congestive heart failure, increased mortality and
stroke. Also discovered was that diabetes was a much stronger risk factor for CVD in
woman than in men. Furthermore, because the FHS followed the same individuals over
time the increase in incidence of diabetes in this population could be reliably determined.
The incidence of diabetes doubled from 1970 to 1990 and this was most noted in obese
individuals. But this information does not clearly explain how the incidence of diabetes
will affect the rates of CVD (Fox, 2010).
In order to understand the increase in incidence of diabetes in the FHS and the
unchanged relative risk o f diabetes as a CVD risk factor, further investigation was done
using a statistical metric known as attributable risk. This metric determines the impact of
a given risk factor on a disease outcome. Applying this metric to the FHS data for the
years 1952-1974 revealed a 5.4% attributable risk o f CVD due to diabetes. The
attributable risk metric was also applied to FHS data for the years 1975-1998 and the
number increased to 8.7% for this time period. This indicated that the risk of CVD due to
diabetes has increased in the FHS population. Fox, (2010), further noted during these
times 1952-1974 and 1974-1998 that other key CVD risk factors such as hypertension
either decreased or remained stable. She concluded that diabetes is a significant risk
factor for CVD in the FHS population. She encouraged further research that would
determine risk factors for CVD that may be more specific for diabetes (Fox, 2010).
The FHS is the longest running population based study in the world and has
provided significant epidemiological information about heart disease, hypertension,
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diabetes, diet, exercise, cigarette smoking, and medications such as aspirin. Some
limitations o f FHS include its tendency to overestimate risk factors; particularly, trying to
generalize risk factors to populations that are not similar to the FHS participants. The
FHS participants are mostly Caucasian middle class adults. This makes it difficult to
generalize results to individuals who do not resemble the FHS participants. Regardless of
these limitations, the FHS has provided valuable data about CVD and serves as a
valuable data bank for future research.
Another interesting population based prospective study, The Hoom Study, was
developed to investigate the prevalence and determinants of glucose tolerance and
cardiovascular risk factors in a randomly selected population in the Netherlands. The
population from which the sample was drawn for this study came from Caucasian males
and females aged 50-70 years, who lived in the Dutch community of Hoom from 1989 to
1992. The data collected included, age, gender, health history including hypertension and
diabetes, renal function (GFR, creatinine, micro-albumin), and various other markers
associated with CVD such as C-reactive protein. Glucose tolerance in this population was
based on the mean o f two oral glucose tolerance test and participants were stratified into
normal glucose tolerance, impaired glucose tolerance, and non-insulin-dependent
diabetes mellitus. The total population of the Hoom cohort was 2,484 participants (Jager
etal., 1998).
In 2002, Henry et al., used a stratified random sample of all individuals from the
initial Hoom Study cohort to investigate the association of mildly impaired renal function
and CVD (Henry et al., 2002). At baseline this population of 631 individuals had mean
age o f 64 years old, 52% were woman, 55% had hypertension and 27% had type 2
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diabetes, meaning that 73% of population either had normal glucose tolerance or had
impaired glucose tolerance. Renal function was estimated in this population by
microalbuminuria and glomerular filtration rate. At 10.2 years follow-up, there were 117
deaths; 50% were from CVD and were highly associated with impaired renal function.
This population based prospective study revealed that there was a 26% increase of death
from CVD when the renal function marker, GFR was decreased (Henry et al., 2002).
While this study, much like the FHS, has limitations due to its population base of
Caucasian participants, it does demonstrate an association between CVD and renal
function. This study also did not discuss the 73% of its population that had either normal
glucose tolerance or had impaired glucose tolerance. However, this was not stated as a
purpose for this study, but given that its population was from the original Hoom cohort,
the data were available but was not discussed.
Unfortunately, more recent investigations have not frilly demonstrated how
cellular dysfunction and inflammatory activity can predict CVD. The association between
renal disease and heart disease is present and thought to be related to these underlying
cellular processes (Levey et al., 1998; Stehouwer et al., 2002). Holvoet et al., in 2001
concluded that LDL is a sensitive biomarker for coronary artery disease (CAD) (Holvoet
et al., 2001). It therefore, would be reasonable to use LDL as a marker for CVD in this
study. What remains to be found is a valid and reliable biomarker that can represent renal
function such as micro-albumin, and if a relationship exists between such a biomarker
and a known CVD marker such as LDL.
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Micro-albumin Levels:
Micro-albumin levels, also termed microalbuminuria, are an increased excretion
of albumin in the urine. Higher levels of micro-albumin have been associated with age,
gender and race. Specifically, there is a higher prevalence in females and non-Hispanic
blacks (Weir, 2007). Micro-albumin can predict CVD mortality and is considered an
independent risk factor for CVD even with adjustment for hypertension (Tagle, Acevedo,
& Vidt, 2003). In individuals with diabetes, micro-albumin is the earliest clinical sign
that indicates vascular damage in the kidneys and it is believed that it is reflective of
vascular damage throughout the body (Weir, 2004).
Hillege et al. (2001), determined that elevated micro-albumin levels in the general
population were independently associated with increased CVD morbidity (Hillege et al.,
2001). This was a cross-sectional cohort study done in the Netherlands. It prospectively
investigated the natural course of microalbuminuria and the relationship between CVD
and renal disease. Participants were asked to submit an early morning urine sample and
answer a questionnaire that determined their current health and health history. The results
revealed increased levels of micro-albumin in individuals with diabetes, hypertension,
and hyperlipidemia. Also significant was advanced age, male gender, smoking and
history of myocardial infarction and stroke. However, when adjustments were made for
high risk groups (individuals with diabetes, hypertension, and hyperlipidemia), the
researchers found that elevated micro-albumin levels were associated with increased
morbidity in the general population. Limitations of this study include the
misclassification that can occur with self-reported histories. Also, its cross-sectional
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design limits the ability to causally relate cardiovascular risk factors, albuminuria and
cardiovascular morbidity.
In their study, Amlov et al., (2005), investigated a sub sample of middle-aged
non-diabetic and non-hypertensive individuals from the FHS (Amlov et al., 2005). It was
determined that urinary albumin excretion, even at low levels, was predictive of CVD.
This suggested that low levels of micro-albumin may be significant in predicting CVD in
all populations. However, in individuals with diabetes, this association is greater with
higher predictive values for CVD (Weir, 2004).
Weir, (2004), discusses in his review article the importance of micro-albumin and
its predictive benefits in individuals with type 2 diabetes for determining renal disease
and CVD. Approximately 28% of individuals with type 2 diabetes have micro
albuminuria. Twenty to forty percent of these individuals, without specific interventions,
will progress to nephropathy and end-stage-renal disease. Weir, (2004), argues that this
figure would likely be higher were if not for the fact that many of these individuals with
diabetes die from myocardial infarctions or strokes before progression to advanced renal
disease can occur. Therefore, the association of elevated micro-albumin and CVD likely
indicates vascular problems throughout the body. A near linear relationship between
raising micro-albumin levels and myocardial infarction and stroke in individuals with
diabetes indicates that micro-albumin is a very significant marker for CVD in this
population (Weir, 2004).
Valmadrid, Klein, Moss and Klein, (2000), concluded that there was higher
mortality from CVD when micro-albumin levels were elevated (Valmadrid, Klein, Moss,
& Klein, 2000). Their population based study used a prospective cohort of 840
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individuals with diabetes from the Wisconsin Epidemiologic Study of Diabetic
Retinopathy (WESDR). Participants provided urine samples during the 1984-1986
examination period. O f the 840 individuals with diabetes, 54.8% had normal urine
samples, 24.8% had microalbuminuria and 20.5% had gross proteinuria. At the 12 year
follow-up, 364 deaths had occurred from cardiovascular disease. Higher mortality from
CVD was noted in individuals with diabetes that had microalbuminuria and proteinuria as
compared to those individuals with diabetes that had normal urine samples. They
concluded that microalbuminuria and gross proteinuria are associated with mortality from
CVD.
The pathologic mechanism for the association between micro-albumin and CVD
is not fully known. There is, however, an association and as a result of this relationship,
micro-albumin can be a useful predictor of CVD in research studies. Although,
Valmadrid et al., (2000), concluded that cardiovascular death rates in diabetics are much
higher when there is microalbuminuria and gross proteinuria, they did not demonstrate
how these levels affect individuals prior to death. It would be beneficial to have a study
using a diabetic population to determine if there is an association between a biomarker
for renal function, such as micro-albumin, and a biomarker for CVD, such as LDL, prior
to death. For this study, micro-albumin will be an independent variable and its
relationship with CVD biomarker LDL will be determined in a diabetic registry
population.

Glycosylated Hemoglobin Levels
Glycosylated hemoglobin (HgbAlc) levels represent the average glucose levels
over two to three months prior to the blood draw. This is a routine test ordered for
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individuals with diabetes at least yearly and more frequently when the diagnosis of
diabetes is new or glycemic control has not been achieved. Levels <5.6% for most
individuals with diabetes is considered within the normal range (Nathan et al., 2008).
However, in older adults (greater than 65), there are increased risks of side effects from
such tight glycemic control. This is likely from changes in body fat composition and the
decline of renal and hepatic function associated with the aging process. Therefore,
individuals with diabetes who are over 65 years old are at increased risk for
hypoglycemia and complications from hypoglycemia, such as changes in cognition and
balance, that can result in falls and diabetic coma. The recommendation is a HgbAlc of
7.0% (Nathan et al., 2008; Stark Casagrande, Fradkin, Saydah, Rust, & Cowie, 2013).
This is interesting to note because research has demonstrated that even a 1% increase in
HgAlc increases CVD risk and could be a contributing factor to the increased risk of
CVD with aging (Khaw et al., 2004).
Khaw, Wareham, Bingham, Luben, Welch & Day (2004), investigated the
association of HgAlc, CVD and mortality in adults (Khaw et al., 2004). In this
prospective population study completed in Norfolk, United Kingdom, 5, 570 women and
4, 662 men were 45-79 years of age. In the 6 year follow-up, all-cause mortality and
CVD was significantly predicted by HgbAlc levels. It was determined that lower
threshold levels for diabetes, such as 5.0% in men and 6.0% in women, could predict
increased risk for CVD Furthermore, a 1% increase in HgAlc was found to be
significant in predicting CVD and mortality in men when >5.4% and in women when
> 6 .0%.
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In a study that investigated the nature of the relationship of HgbAlc levels and
cardiovascular events in chronic heart failure, Gerstein, Swedberg, Carlsson, et al.,
(2008), demonstrated that HgbAlc is an independent progressive risk factor for
cardiovascular mortality and morbidity (Gerstein et al., 2008). O f 2,412 participants, 907
individuals had diabetes. The sample for this study was drawn from the Candesartan in
Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Inclusion criteria for the study included having had at least one HgbAlc reading during
the 34 month study. Data analysis revealed that in individuals with symptomatic chronic
heart failure, the HbgAlc was found to be strongly associated with risk factors for
cardiovascular events regardless of the presences of diabetes. In this study,
cardiovascular mortality and morbidity increased by approximately 25% for every
1% increase in the level of HgbAlc (Gerstein et al., 2008).
There is evidence that HgbAlc is associated with CVD even at non-diabetic
levels. However, the nature of this association between glycosylated hemoglobin and
cardiovascular disease is not fully known. This study will extract HgbAlc values from a
diabetic registry to determine the degree of association for this study’s CVD biomarker,
LDL.

Summary
This chapter reviewed the literature that are relevant to the investigation of the
relationships between the variables. The conceptual framework for this study described
the predicted relationships among the variables. The relevant research in cardiovascular
disease and the use o f glycosylated hemoglobin levels, micro-albumin levels and select
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demographics (age, gender, socioeconomic status) was discussed. The methodology for
this investigation will be discussed in Chapter Three.

Chapter Three
METHODOLOGY
Introduction
The purpose o f this retrospective descriptive data-based study was to investigate
the relationship between glycosylated hemoglobin levels (HgbAlc), micro-albumin
levels, select demographics and low density lipoprotein levels (LDL). The data were
extracted from a diabetic registry data bank from a Central California health care
organization. This chapter will present the research design and methodology that was
used in the investigation. There will also be a discussion addressing the protection of
human subjects.

Setting and Database
This study used data collected from a Central California health maintenance
organization (HMO). This HMO provides primary health care to people living in Kern
County. Kern County is the eleventh most populated county in the state of California
with over 860,000 people. The county’s main sources of economic growth are from the
agricultural industry and the extraction of petroleum. Also important to Kern County’s
economic viability is the aviation, space and military industry.
20
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Therefore, the majority o f this HMO’s population is derived from individuals working in
agricultural, petroleum and military industries (kemcounty.com).
This HMO’s diabetic registry was used as the database for this study. The registry
was developed to track healthcare information for the HMO’s population o f diabetic
patients. The data collected included demographic and clinical information. The
demographic data included the individual’s date of birth, gender, and zip code. Not
included was the individual’s ethnicity, as this information is not consistently recorded in
this HMO’s patient’s health history. Consistently collected clinical information included
laboratory values for glycosylated hemoglobin levels (HgbAlc), micro-albumin levels
and low density lipoprotein levels (LDL). Additional clinical information collected
included yes/no responses to the following: A foot exam completed, including
monofilament testing, and by which type of provider; diabetic eye exam, and blood
pressure measurement. Some o f this additional clinical information is inconsistently
collected and recorded in the registry.
This data are automatically input into the database on a daily basis from the
electronic medical record (EMR). The information was captured by diagnosis codes,
laboratory claim reports and laboratory results for each individual in the diabetic registry.
Once a patient was added to the diabetic registry their EMR is tagged to copy over
information into the registry. New imputed information was reviewed bimonthly by the
systems developer. The systems operator confirmed that inputted information was
accurate for patient, diagnosis, lab values, and all other clinical data. For those HMO
patients who do not have a medical record, the information was entered manually into the
registry. The data in this diabetic registry were stored and retrieved for healthcare
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regulatory and accreditation purposes. It has not been used as a database for research
purposes in the past (Monroy, 2013).

Research Design
This study used a retrospective descriptive correlation design using de-identified
data previously collected from patients. Data were housed within a health care
organization’s diabetic registry and spanned from January 1,2011 to December 31,2012.
All de-identified data that were to be abstracted for investigation will have at least one
numerical entry for all of the following, HgbAlc, micro-albumin, and low density
lipoprotein levels. Each case included select demographics; specifically, age, gender and
socio-economic status. No cases with missing data were used in this study. The study
design that was chosen supported the investigation of associations between the variables.
As background, retrospective design works with large sample sizes and therefore, lends
itself well to data abstraction from registries from which a large number of cases can be
obtained. There is also the benefit of time efficiencies, as the data have already been
collected and stored in a databank For this study, data abstraction and analysis will allow
the associations, or lack thereof, between the independent and dependent variables to be
revealed. The independent variables for this study included HgbAlc levels, micro
albumin levels, and select demographics (age, gender, socio-economic status). The
dependent variable was the LDL levels.

Study Aims
Aim 1: To describe HgbAlc levels, micro-albumin levels, LDL levels and select
demographics (age, gender, socio-economic status).
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Aim 2: To determine if there was a relationship between LDL levels and HgbAlc
levels.
Aim 3: To determine if there was a relationship between LDL levels and micro
albumin levels.
Aim 4: To determine if there was a relationship between LDL levels and select
case demographics (age, gender, socio-economic status).
Aim 5: To determine the degree of variability in LDL levels accounted for by
HgbAlc levels, micro-albumin levels and select case demographics (age,
gender, socio-economic status).

Dependent Variable
The dependent variable, LDL, is one o f the five major groups of lipoproteins that
enable transport of fat molecules and cholesterol into artery walls. Specifically, LDL is a
very large molecule that can transport numerous fat molecules and cholesterol into the
artery wall. These fat molecules and cholesterol are retained in the wall by arterial
proteoglycans and macrophages that engulf the LDL particles causing the formation of
plaque. It is this buildup of plaque that can result in heart attack, peripheral vascular
disease, and stroke (Krauss, 1995). Numerous studies have identified LDL as a predictive
value in the development of heart disease (Niskanen, Turpeinen, Penttila, & Uusitupa,
1998).
The LDL is a numerical value that is obtained via a laboratory blood test. It is part
of a lipid profile panel and is obtained on nearly all patients with diabetes or others who
have risk factors for heart disease. This makes the LDL readily available for use in
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research studies (Howard, et. al., 2000). Low density lipoprotein levels (LDL) for each
case were downloaded from the database

Independent Variables
The independent variables, HgbAlc and micro-albumin, are laboratory values that
provide information about diabetes and urine protein levels. The HgbAlc is a blood test
used to ascertain glycemic control in a diabetic. The value of the HgbAlc is determined
by exposure to plasma glucose with higher values indicating increased blood glucose
levels. This lab value has become the standard of care in determining how well diabetics
are managing their blood glucose levels over a period of months (Nathan et al., 2008).
Nearly all patients with diabetes that are followed by health care professionals regularly
will have at least one to four HgbAlc values done within a year (Stark Casagrande et al.,
2013). Also, part of the laboratory test for patients with diabetes includes a urine test to
check protein levels.
Micro-albumin is a urinary laboratory test that indicates how much protein
(albumin) the kidneys are excreting. This is done as a random urine test. Increased levels
of micro-albumin indicate that there is high permeability for albumin in the renal
glomerulus, meaning a higher risk that renal injury occurring (Andersen et al., 2000).
Demographic data were downloaded for each case and included age, gender and
zip code (proxy for socio-economic status) for each case. Age was measured in years and
was interval data. Gender was measured as male or female and was categorical level data.
The zip code was used as a proxy for socio-economic status (Geronimus & Bound, 1998)
and was categorical level data.
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Inclusion and Exclusion Criteria
Inclusion criteria: Cases that had a recorded diagnosis of diabetes and at least one
value for each of the following: LDL level, HgbAlc level and micro-albumin level from
the time period of January, 1 2011 to December 31,2012.
Exclusion Criteria: All cases for the time period of January 1,2011 to December
31, 2012 that did not have values for LDL level, HgbAlc level, or micro-albumin level
entered into the diabetes registry were excluded from the study. No child cases (under 18
years), expired cases, or cases of those who were no longer members of the HMO at the
time o f the data extraction were used. Also all cases that did not have electronic medical
records were excluded.

Data Retrieval Procedures
The diabetic registry of a health care organization in Central California was used
for this study. Permission was obtained to utilize the organization’s database for this
study (see Appendix B). Per organizational protocol, the organization’s data manager
used study inclusion and exclusion criteria to extract the data. A preliminary data query
by the data manager estimated the number of cases that meet the inclusion and exclusion
criteria was to be just over 880 cases (Monroy, 2013). The following data were extracted
into an Excel spreadsheet: HgbAlc levels, micro-albumin levels, select demographics
(age, gender, socio-economic status) and LDL levels.

Sample Size, Power and Significance
It is important to establish the sample size necessary for the statistical analysis
with considerations of power, population effect size, and level of significance (Huck,
2008). For the purposes of this study, the alpha level was set at.05. This equated to a
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0.95 % probability and is equivalent to a 95% confidence level in order to decrease the
chances of committing a type I error, a false positive claim. The power of the significance
test was the probability of rejecting the null hypotheses when the null hypotheses is false,
considered a type II error, a false negative claim. Next, for this study an acceptable level
of power was .80 and was utilized to determine the sample size (Huck, 2008). Effect size
was considered next. When choosing an effect size, researchers decide how small a
difference they are willing to accept and still find the results worthwhile (Huck, 2008).
For this study the effect size that was determined to be clinically significant was .25.
This study involved several different analyses. Each type of analysis required a
different sample size and o f these analyses, the multiple regression required the most
conservative sample size to detect a significant model. With the alpha set at .05, to
achieve a power of .80 and an effect size .25, the minimum sample size of 57 was
determined based on A-priori sample size calculator. However, a sample size of 300 was
chosen as a reasonable sample to be representative of the database ("Bayes’s Theorem ",
2013). Once all inclusion and exclusion criteria were met, cases were randomized to
obtain a sample size of 300 cases by using a random sample calculator.

Data Analysis
The data were transferred from an Excel spreadsheet into SPSS Windows version
22 for analysis. The following analyses were used to address each aim: descriptive
statistics, Pearson r, and multiple regression. The analysis for each aim are explained.
Aim 1: To describe HgbAlc levels, micro-albumin levels, LDL levels and select
demographics (age, gender, socio-economic status). Descriptive statistics will be
conducted to describe the independent and dependent variables. This included frequency
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and percentages for categorical data and means, standard deviation, and ranges for
continuous data.
The following aims were addressed by using the Pearson r correlation to
determine the relationships between these interval data variables. Aim 2: To determine if
there was a relationship between mean LDL, levels and HgbAlc levels. Aim 3: To
determine if there was a relationship between mean LDL levels and micro-albumin
levels. Aim 4: To determine if there was a relationship between mean LDL levels and
select case demographics (age, gender, socio-economic status).
Multiple regression will be utilized to address Aim 5. Aim 5: To determine the
degree o f variability in LDL levels accounted for by HgbAlc levels, micro-albumin
levels and select case demographics (age, gender, socio-economic status).
Multiple Regression
This study sought to determine if there were significant relationships between the
independent variables and the dependent variable and to what degree the variation in the
dependent variable was explained by the independent variables. As background,
regression analysis is used when the primary purpose of a study is to describe
relationships among independent variables and account for variability in a dependent
variable. Regression analysis results can be displayed using scatter plots where the points
on the plot represent the results. The X-axis is the independent variable and the
dependent variable is the Y-axis. The spread of the points on the plot determines the
magnitude o f relationship among the variables. The strength of these relationships
determines the amount of variation in the Y variable as explained by the X variable.
Demonstrating strong relationships between variables using regression analysis was the
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goal of the study and so several important factors were considered (Mertler & Vannatta,
2005).
Important factors to consider in regression analysis include the slope of the
regression line, where the points are scattered around the line and the point that the
regression line crosses the Y-axis. Once these factors are considered, a regression
equation can be calculated. However, multicollinearity must be addressed as part of an
analysis. Multicollinearity occurs when there are moderate to high intercorrelations
among the independent variables. This can result in overlapping information, limiting the
size of multiple correlation and increasing the variance of regression coefficients,
resulting in an unstable equation. To prevent problems with multicollinearity in this
study, a tolerance test was performed to measure the collinearity among the independent
variables. If there is a problem with multicollinearity, it can be managed by either
deleting one of the problematic variables or by combining them to create a single
construct. Lastly, sample size needs to be considered. For a reliable equation, the sample
size («) should be greater than/equal to 104 plus dependent variable/predictor (k). Other
factors such as power, population effect size and level of significance also must be
considered when determining sample size for analysis as described above (Mertler &
Vannatta, 2005).

Limitations o f the Study
Several limitations were anticipated. Most significant to note was that there was
no ethnic information for this databank population. This makes it very difficult to
generalize the results o f this study to other populations. The zip code was used proxy for
socio-economic status. While all cases had at least one value for each clinical variable, it
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was anticipated that some cases might have numerous values collected over a range of
time. While mean scores were used for study analysis; there was a possibility of
overestimation of the relationships among the variables. Lastly, it was known that such
disease specific databank registries designed to meet regulatory and accreditation
requirements generally have limited numbers o f variables restricting researchers from
fully characterizing the cases.

Protection of Human Subjects
A retrospective data analysis has low risk for harm to human subjects. It was
anticipated that informed consent would not be required because there was no contact
with human subjects; the researcher only used data extracted from a diabetic registry.
Anonymity was addressed as follows: The data manager extracted the cases from the
diabetic registry and insured that all data were de-identified prior to providing the data to
the investigator. Confidentiality of the de-identified data were important to the health
care organization; therefore, only aggregate data were reported in the results. No
individual case data or raw data were included in any reports. For the purposes of
analysis, raw case data resided on the investigator’s password protected computer. Data
extraction occurred after receiving study level of oversight determination from the
institutional review board (IRB) of the University of San Diego. The level of oversight
was exempt. The health care organization did not have an IRB.

Conclusion
This chapter explored the methodology for this investigation with rationales for
sampling and sample size. The dependent and independent variables were defined for this
study. The inclusion and exclusion criteria for the study cases were explained as were the
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data collection and data analysis procedures. Lastly, there was a discussion addressing the
protection of human subjects. Results of the analysis are discussed in Chapter Four.
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Chapter Four
STUDY RESULTS
The purpose of this study was to investigate the relationship between glycosylated
hemoglobin levels (HgbAlc), micro-albumin levels, select demographics (age, gender,
socio-economic status), and low density lipoprotein levels (LDL) in a diabetic
population. The cases for this study were drawn from a diabetic registry. In this chapter,
study results will be presented, including sample characteristics. The descriptive profile
analysis o f the sample will be presented. The results for each research aim will be
explained.

Community Characteristics
This study used data collected from a Central California Health Maintenance
Organization (HMO). This HMO provides primary health care in Kern County. There are
over 860,000 people living in Kern County making it the eleventh most populated county
in California. The county’s main sources of economic growth are from agricultural and
petroleum industries. Also well represented in Kern County economics are the
educational, transportation, and military industries. The largest ethnic groups in Kern
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County, as reported by City-Data.com (2014), are Hispanic at close to 51%, White at
nearly 37%, and Black, at approximately 5%.

HMO Characteristics
The HMO used for this study was established in Kern County over 30 years ago
and is affiliated with a nationally recognized network of physicians. Their mission is to
prioritize patient satisfaction and education in all medical and service activities. They
achieve their mission by offering numerous locations for healthcare services throughout
the county. They provide patient education and are also involved in local healthcare
charity events for cancer, women’s health, cardiovascular health, and child health care
programs. There are five campuses that house the HMO providers located in Kern
County. Also, throughout the county there are numerous private practice physician
offices that are affiliated with the HMO through the physician network. As a result of
their association with the physician network, their HMO patients have more choices for
healthcare throughout the entire county of Kem, website 10/11/14. Several years ago the
HMO developed a diabetic registry to track healthcare information for regulatory and
accreditation requirements (Monroy, 2013). It was this data bank that was used for this
study.

Diabetic Registry
The data collected included demographic and clinical information. The
demographic data included the individual’s date of birth, gender, and zip code. Clinical
information included laboratory values for HgbAlc, micro-albumin, and LDL. Additional
information in the registry was inconsistently collected and therefore, was not used for
this study.
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Sample
The inclusion criteria for each case was: a) a diagnosis of diabetes, b) at least one
value for each o f the following: LDL level, HgbAlc level, and micro-albumin level from
the time period of January 1,2011 to December 31,2012. The exclusion criteria for this
study were cases under 18 years of age, expired cases, cases who were no longer
members of the HMO at the time of the data extraction, and cases that did not have an
electronic medical record. There were 883 cases that met the inclusion criteria for this
study. The minimum sample size of 57 was determined based on A-priori sample size
calculator. However, a sample size of 300 was chosen as a reasonable sample to be
representative of the database (“Bayes’s Theorem”, 2013). A random sample calculator
determined the 300 cases that were used to represent this study’s population.
Micro-albumin levels for eight cases were three standard deviations from mean.
Further investigation of these eight cases revealed that they were univariate outliers. As
univariate outlier, this meant that the other variables for these eight cases were within the
normal distribution for the other variables (Katz, 2006; Mertler & Vannatta, 2005). The
final population size used for this study was 292 cases for all variables except median
income that had eleven cases with missing data (n=281).

Descriptive Findings
Aim 1: Describe HgbAlc levels, micro-albumin levels, LDL levels and select
demographics (age, gender, socio-economic status). Descriptive statistics were computed
to describe these variables and included frequency and percentages for categorical data
and means, standard deviation, and ranges for continuous data.
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The mean age for this sample was 73 ±12 years old. Mean income was
$48,264 ±$16,700 per year, mean HgbAlc was 7.0 ±1.3 mg/dl, and mean LDL of
95.2 ±30 mg/dl. The majority of the sample was female (n= 165; 57%) with the only
significant difference between females and males being the LDL means (male 90.0 vs.
female 99.0; t= -2.436, p = 0.015). Table 1 summarizes the descriptive statistics for the
continuous data variables.

Table 1. Descriptive Statistics: Age, Median Income, HgbAlc, Micro-albumin, and LDL
Age (n=292)

M = 73
SD = 12

Range
3 5 -9 7

Income (n=281)

M = 48,264
SD = 16,700

Range
29,910-96,322

HgbAlc mg/dl (n=292)

M = 7.0
SD = 1.3

Range
5 .3 -1 3 .5

Micro-albumin mg/dl (n=292)

M = 49.1
SD = 86.9

Range
0.4 -6 3 0 .6

LDL mg/dl (n=292)

M = 95.2
SD = 30.0

Range
27.0-313.0

Correlations
Aims 2 and 3 were to determine if there was a relationship between LDL levels
and the other two laboratory values of HgbAlc and micro-albumin, respectively. Aim 4
was to determine if there was a relationship between LDL levels and select case
demographics. Pearson r correlation and point biserial (run in SPSS as Pearson r)
statistics were used to determine any relationships between the dependent variable and
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the independent variables. The Pearson r correlations are significant if p values are equal
to or lesser than 0.05 (Field, 2005).
Aim 2: Determine if there was a relationship between LDL levels and HgbAlc
levels. Results indicated there was not a statistically significant relationship, r = .019,p >
0.376.
Aim 3: Determine if there was a relationship between LDL levels and micro
albumin levels. Results indicated there was not a significant relationship, r = -.010,/> >
0.435.
Aim 4: Determine if there was a relationship between LDL levels and select case
demographics (age, gender, socio-economic status as measured by median income).
Results indicated there was not a significant relationship between LDL and age or with
LDL and median income: Age r - -.072, p > 0.111. Median income r = .056, /? > 0.177.
There was a statistically significant relationship between LDL level and gender,
r =.138 andp > 0.009.
Aim 5 will be addressed by discussing the regression analysis.

Regression
Aim 5: Determine the degree of variability in LDL levels accounted for by
HgbAlc levels, micro-albumin levels, and select case demographics. A two- model
regression analysis was conducted using a block design. Model 1 (gender as the only
independent variable) revealed an R value of 0.138; R2 value of 0.019;p = 0.020. The
A-priori identified complete model, with all of the independent variables, revealed the
study data did not fit the model: R value of .173; R2 value of 0.030; p = 0.134. While the
R2 value for these independent variables accounted for three percent of the variation of
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LDL levels, the model was not significant. Ninety seven percent (97%) of the variability
in LDL level was unaccounted for in the specified model. The possible reasons for this
finding will be further discussed in Chapter Five.

Summary o f Results
The results presented in this chapter included a descriptive profile analysis o f the
sample population and results of the research aims. This analysis revealed there was only
one independent variable (gender) that demonstrated a relationship with the dependent
variable. However, gender only accounted for 1.9% of the variance in the dependent
variable. The combined variability of the independent variables in this study accounted
for only three percent variance in the dependent variable and was not statistically
significant. This indicated the overall model was not a good fit. There will be a
discussion of the analysis and an interpretation o f the results in Chapter Five.

Chapter Five
DISCUSSION OF FINDINGS
The purpose of this study was to investigate cardiovascular risk factors in a
diabetic population. A retrospective study was conducted using a diabetic registry from a
Health Maintenance Organization (HMO). The consistently collected data from this
diabetic registry was analyzed to determine if there were any relationships between the
independent variables and the dependent variable. The results determined the
independent variables, glycosylated hemoglobin levels (HgbAlc), micro-albumin levels,
and select demographics (age, socio-economic status) with the exception of gender, did
not reveal any significant relationship to the dependent variable, low density lipoprotein
levels (LDL). This chapter will present a summary of findings and limitations of this
study. Lastly, implications for nursing practice and future research will be presented.

Sample Demographic Characteristics
The demographic variables for this study included age, gender, and socio
economic status. The sample had a mean age of 73 years with more females than males.
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This is a fairly consistent finding with other cardiovascular disease studies and findings
associated with diabetes. Regitz-Zagrosek, Lehmkuhl and Weickert in their 2006 review
of gender and cardiovascular disease noted that women develop cardiovascular disease
later in life and also live longer that men. They state age affects woman and men
differently. Men develop metabolic problems such as hyperlipidemia and diabetes at a
younger age then women but women will have a higher prevalence of these disease
processes later in life, living longer with these diseases. Regitz-Zagrosek et al., 2006,
suggest the link may be hormone related, however, further research is indicated. Zip
codes with data linked to median income were used as a proxy for socio-economic status
(Geronimus & Bound, 1998). The sample mean median income was $48,264 (range
$30,909 to $96,322). Financially, for this study’s sample, this was slightly lower than the
national median income of $51,939 US census Bureau, website Sept 2014. There is
evidence that lower income levels are associated with risk factors for both diabetes and
CVD in the United States (Kanjilal et al, 2006). It is believed that individuals with lower
income levels have less access to care and likely more complications associated with the
disease process when compared to individuals with higher income (Bonow, Smaha,
Smith, Mensah, & Lenfant, 2002).
Interestingly, for this dissertation study, results did not reveal an association
between median income and the marker for cardiovascular disease marker, LDL. This
may very likely be because this study’s sample was drawn from an HMO and as a result,
his sample had access to healthcare. For other populations in Kern County that are not
associated with an HMO this might be a different finding.
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Sample Clinical Characteristics
Clinical variables for this study included HgbAlc, micro-albumin, and LDL. The
mean HgbAlc for this sample was 7.0mg/dl. The recommended level for most
individuals with diabetes is considered within the normal range when the HgbAlc level is
below <5.6mg/dl (Nathan et al., 2008). However, based on the mean age of 73 years for
this study’s sample, a HgbAlc level of 7.0mg/dl is considered within the normal range as
there are significant risk for hypoglycemia in individuals with diabetes over 65 years old
(Nathan et al., 2008; Stark Casagrande, Fradkin, Saydah, Rust, & Cowie, 2013).
Based on national recommendations for the general population (not individuals
with diabetes), the LDL goal is <99mg/dl (ADA, 2013). However, a sample of diabetic
patients was used for this study. The national goal for individuals with diabetes with
more than one risk factor for cardiovascular disease (which would include diabetes) is a
LDL o f <70mg/dl (ADA, 2013). Therefore, this sample had at least one known risk factor
for cardiovascular disease (ADA, 2013). Due to the limited number of data topics
contained in the diabetic registry used for this study, determining if other risk factors
existed was not possible. Therefore, a mean LDL of 95.2 may be an elevated level in this
sample population if it could have been determined that the patients had more than one
risk factor.
The micro-albumin level mean (49.1 mg/dl) for this study’s sample was above
normal for both the general population and for individuals with diabetes (Hillege et al.,
2001). While not significant, of interest was that the mean values for females (53mg/dl)
were nearly lOmg/dl higher than males micro-albumin levels (44.2mg/dl). Other findings
are mixed regarding this association between micro-albumin and gender. The current
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study’s finding is consistent with a literature review using data from the National Health
and Nutrition Examination Survey (NHANES) (Weir, 2007). The review revealed a
higher prevalence o f micro-albumin levels associated with female gender. However, a
different study reported a higher prevalence of micro-albumin levels was associated with
male gender (Hillege et al., 2001). It was recommended that these findings be further
investigated to determine the extent of the relationships (Hillege et.al, 2001; Weir, 2007).
This current study demonstrated with this sample, although not generalizable due to lack
o f significance, that females had higher micro-albumin levels compared to males.

Associations with LDL Levels in the Sample
No significant associations, with the exception o f gender to LDL levels, were
found between the independent variables and the dependent variable in this study.
Specifically, the independent variables of age, median income, HgbAlc levels, and
micro-albumin levels were not significantly associated with the dependent variable, LDL.
The relationship of gender with LDL levels will be discussed next. Then the possible
reasons for the lack o f association among the remaining variables and LDL levels will be
discussed.
Gender and LDL Association
For this study, only one variable, gender, was found to be correlated with the
dependent variable, LDL r =.138,/?>0.009. Gender in this study revealed the following
mean LDL levels: males 90.0 ± 26.5 mg/dl, vs. females 99.0 ± 32.0 mg/dl, t =-2.436,/? =
0.015. Holvoet et al., in 2001 concluded that LDL levels were a sensitive biomarker for
coronary artery disease (CAD) in men and women. They compared LDL levels to the
Global Risk Assessment Scoring (GRAS) that was developed to by the American College
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of Cardiology and the American Heart Association as a guide for primary prevention of
CAD. The GRAS scoring is based on age, high density lipoprotein levels (HDL), total
cholesterol levels, diabetes, smoking, systolic blood pressure. Holvoet et al., (2001)
determined that LDL levels alone were a sensitive marker of CAD in their study; with
LDL level having a 76% positive predictive value compared to GRAS that had only a
20% positive predictive value in predicting CAD. They further found the positive
predictive value of the LDL marker was higher in females (81%) than in males (55%).
This indicates that LDL is better for predicting CAD than GRAS for females.
This dissertation study did find a correlation between gender and LDL levels. It
also found higher LDL levels in females when compared with males. However, gender
only accounted for 1.9 % of variance in the regression model, while all the independent
variables combined accounted for 3% of the variance. This indicated that 97% of
variance could not be accounted for in this regression model for this study. This will be
discussed further in the next section.

Regression Analysis
In this study, a regression analysis was conducted dsing an A-priori model to
determine which independent variables (age, gender, median income, HgbAlc levels, and
micro-albumin levels) would contribute to a significant amount of variance in the
dependent variable, LDL. However, the sample data did not fit the regression model. The
possible reasons for this will be discussed next.
According to a number of authors when results do not reveal relationships that
were anticipated, it is recommended that sample size should be re-evaluated (Field, 2005;
Huck 2008; Mertler & Vannatta, 2005). Based on the alpha (.05), power (.80), effect size
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(.25), and the method of analysis (multiple regression), minimum sample size of 57 was
determined to be sufficient to detect relationships in this study. However, because a
relatively large sample was available, a sample size of 300 was chosen as a reasonable
sample size to be representative of the database (“Bayes’s Theorem”, 2013). There were
eight cases that had micro-albumin levels that were determined to be three standard
deviations from the mean for that study variable and were therefore removed (Katz, 2006;
Mertler & Vannatta, 2005). Thus, the final sample size for this study was 292. The
sample size was determined to be of adequate size, being well over the minimum
calculated sample size of 57.
The study findings only determined a three percent variance in the LDL value;
meaning that 97% of variance was unaccounted for with this model. There are three
possible reasons for non-significance of variance in a model. These include; 1) no linear
relationship at the bivariate analysis level; 2) problems with outlier data points; and 3)
missing explanatory variables.
The first reason for data not fitting an A-priori regression model is there is
actually no linear relationship at the bivariate analysis level among the variables. Field
(2005) explains that correlation between variables is demonstrated when the mean for one
variable increases or decreases the as mean for the other does so as well. This relationship
can be either positive or negative. No correlation between the variables indicates a lack of
a linear relationship (Field, 2005). In this study there was only one pair of variables that
demonstrated a significant bivariate relationship and that was between gender and LDL.
Second, there can be a problem with outlier data points. If there are data points
that are over three standard deviations from the mean, is can change the regression line
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such that there is no line or that the line is pulled positively or negatively away from the
main data points (Field, 2005; Mertler & Vannatta, 2005). In this study, there was a
univariate outlier that was managed and therefore this would not likely explain the lack of
data-to-model fit in this study.
Finally, the third possible reason that this study’s data did not fit the model was
that the “true” explanatory variables were not included in the study. Retrospective studies
using clinical databases can have limited data available to utilize as research variables as
this study most likely demonstrated. However, population-based retrospective studies that
have used large databases designed for longitudinal research, such as the Framingham
Heart Study (FHS) databank have been successful in determining relationships among
numerous variables. This is likely due to the numerous choices of variables that
researchers have when using such large databases such data typically includes medical
and lifestyle history, laboratory tests and physical examinations. Researchers have
successfully used the FHS data bank to discover many of the risk factors for heart disease
and strokes including smoking, high blood pressure, low levels of activity, high
cholesterol levels, and electrocardiogram abnormalities (Dawber, 1960; Kannel, Dawber,
Kagan, Revotskie, & Stokes, 1961; Kannel, 1967; Wolf, Kannel, & McNamara, 1970).
This study used a diabetic registry that was designed to track health care
information for regulatory and accreditation requirements (Monroy, 2013). This was
problematic because the categories of data that were available for use within this diabetic
registry were limited. This will be further discussed in the limitations section.

Exploring the Diabetic Registry - 44

Limitations o f the Study
This section will discuss the use of proxy data, data that was inconsistently
collected, and data categories that were not part o f the database. All three of these
situations can be limitations in research studies.
First, using proxy data can impose limitations in research. This study used
zip code as a proxy for median income. Geronimus and Bound in their 1998 study,
investigated using zip codes to better identify the economic status of individuals to be
used in healthcare research. They compared this to detailed lengthy government surveys
over a 20-year period. It was concluded that the use of zip codes is less costly and does
give an accurate economic assessment of a given population. However, other information
collected by zip code, such as education and ethnicity are less accurate (Geronimus &
Bound, 1998). This study used zip code as a proxy for median income and it did provide
financial information about the sample that was fairly consistent with national numbers
for median income.
Second, some types of data included in the database were so inconsistently
collected they could not be included in this study. The data inconsistently collected in this
diabetic registry included; 1) blood pressure measurement; 2) diabetic foot exam; 3)
monofilament test for sensation in the feet; and 4) diabetic eye exam. These categories of
data could not be used in this study because the collection of this information in the data
bank was sparse.
Finally, the most significant limitation of this study may have been the very
limited availability o f categories of data in the HMO’s database. For example race and
ethnicity were not included in this database. Examples of clinical data categories not
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captured included; 1) high density lipoprotein levels; 2) age at diagnosis of diabetes; 3)
diabetic medication history (none, oral, insulin, or both oral and insulin); 4) smoking
history; 5) health history information such as: heart attack, cerebral vascular accident,
renal disease, and dialysis. Having additional demographics and clinical data available
for use in this study would have assisted in better characterizing the sample and may have
provided additional variables to explain more variance in the model.
This study was missing valuable data that would have helped not only to define
the study sample but may also have allowed the findings to be generalized beyond this
study. In summary, this disease specific databank as designed to meet regulatory and
accreditation requirements and as such had limited numbers of useful variables restricting
full characterization o f the sample and generalizability o f the findings.

Implications for Nursing
Nursing Practice
Cardiovascular disease (CVD) is a significant health problem and nurses are vital
in assisting patients in improving their cardiovascular health (Veazie et al., 2005).
Although there was only one significant finding in this study, the study may provide
useful information for nurses. As an example, it is known that the sample drawn from this
diabetic registry had HgbAlc levels that met American Diabetic Association
recommendations (ADA, 2013). On the other hand, the LDL levels in this sample
population are likely too high and should be closer to 70 mg/dl instead of 95.2 mg/dl.
This is because it is very likely that many of the individuals in this diabetic registry have
other cardiovascular risk factors. This is useful information for nurses. Nurses should
look beyond just HgbAlc levels and utilize evidence-based guidelines as interventions to
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lower the LDL level in patients with diabetes. Ongoing monitoring by nurses of both
HgbAlc levels and LDL levels are important in order to maintain cardiovascular health,
as well as overall health.
The mean micro-albumin levels for this sample were above normal. Normal levels
for micro-albumin are 0-17 mg/dl for the general population. Differences in these levels
can be related to the measure utilized by different laboratories. However, any level over
20 mg/dl should be considered elevated (Stehouwer & Smulders, 2006). On the other
hand, micro-albumin levels for individuals with diabetes have yet to be determined but
when evidence is eventually available, the recommended levels will likely be lower than
lOmg/dl (Weir, 2007).
Elevated micro-albumin levels are considered to be reflective of renal damage as
well as CVD (Levey et al., 1998; Stehouwer & Smulders, 2006; Lane, 2004). Garg and
Bakris, in their 2002 review of the literature, determined that patients with elevated
micro-albumin levels also had higher blood pressure levels. They discussed that even
micro-albumin levels o f 28-30mg/dl were associated with higher blood pressure readings
when compared to micro-albumin levels that were <20mg/dl. They recommend further
research to investigate if micro-albumin can be used to as a clinical marker for blood
pressure control, as well as for renal disease.
Considering the association of elevated micro-albumin levels and blood pressure
measurement, interventions by nurses to lower blood pressure in this diabetic registry
population may also help lower the micro-albumin levels. By adding blood pressure
measurements to diabetic registries and trending those measurements over time, nurses
would be able to recommend interventions that may assist individuals with diabetes in
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lowering their blood pressure. Nurses would be able to achieve this goal by providing
diet, exercise, and medication management education to this diabetic registry population.

Research
A number o f subsequent research studies can be recommended to continue this
study’s line of inquiry. These include further expansion of the study conceptual
framework to include more variables, changing the dependent variable to a different
variable reflective of CVD. This study used a conceptual framework to predict the
possible relationships among the variables. See figure 1. An expanded version of this
basic framework may be useful in future nursing research. First, the demographic
measurements could be expanded to include race and ethnicity. With different rates of
diabetes occurring among different races and ethnicities, it is important to investigate the
relationship among all of the framework variables in the context of race and ethnicity.
Second, the clinical characteristics could be expanded to additional measurements such as
blood pressure and HDL levels.
A different biomarker for cardiovascular disease may be a prudent next step. A
better clinical marker for cardiovascular risk might be micro-albumin levels. There is a
demonstrated relationship between elevated micro-albumin levels and increased risk of
CVD (Amlov et al., 2005). Weir (2004) describes that micro-albumin is the earliest
clinical sign of vascular damage in the kidneys and it is believed it is reflective of
vascular damage throughout the body.
Changing the biomarker for CVD to micro-albumin and adding additional
variables may be beneficial in better determining cardiovascular risk factors in a diabetic
population. Fox (2010) describes the current state of knowledge obtained from the
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Framingham Heart Study (FHS). She evaluated diabetes and CVD in the FHS population
and concluded there was an association between the two disease processes. She argued
for further research that would determine risk factors for CVD that may be more specific
for diabetes (Fox, 2010).

Summary
The purpose of this study was to investigate cardiovascular risk factors in a
diabetic population. A Health Maintenance Organization’s diabetic registry was used as
the data source. With the exception of gender and low density lipoprotein levels, the
results did not reveal any significant relationships among the variables. The most likely
reason for this result was the limited types of data available from the diabetic registry that
could be used as categories of data. Although this particular data bank was limited
because it was developed specifically to track health care information for regulatory and
accreditation requirements, it could be redesigned in order to be used in future research
studies. All data would need to be collected on a consistent basis and data categories
expanded. This data bank would likely be very useful in investigating cardiovascular risk
factors in a diabetic population with appropriate changes.

Conclusion
Cardiovascular disease is a significant national health problem. It affects millions
of people and is the leading cause of death in the United States. The estimated cost of
care is over $393.5 billion annually (Pal, 2006; Veazie et al., 2005). The problem was so
significant in the early 20th century that the National Heart Institute and the National
Heart, Lung, and Blood Institute partnered with Boston University in an ambitious
project. The goal was to determine common cardiovascular risk factors in a population
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that had no obvious symptoms o f cardiovascular disease at the time of enrollment. This
population-based prospective family cohort study, the Framingham Heart Study, has been
instrumental in obtaining valuable data about cardiovascular disease. Their ground
breaking discoveries include identifying that cigarette smoking, low levels of activity,
high cholesterol levels, high blood pressure, and electrocardiogram abnormalities are
associated with increased risk of heart disease and strokes. Numerous researchers have
used this data bank to investigate many aspects o f cardiovascular health and how other
disease processes such as cancer and diabetes can compound the effects of cardiovascular
complications.
Fox (2010), reported early on in the Framingham Heart Study, that diabetes was
recognized as a risk factor for cardiovascular disease. In her report she cited a two to four
fold increased risk of heart attack, peripheral arterial disease, congestive heart failure,
stroke and increased mortality associated with diabetes. She encouraged further research
to determine risk factors for cardiovascular disease that may be more specific for diabetes
(Fox, 2010).
In this dissertation study a disease registry was used to determine cardiovascular
risk factors in a diabetic population. The results revealed an association between gender
and the cardiovascular biomarker for this study, low density lipoprotein levels. However,
the association contributed to small variance in the regression model. It has been
discussed in this chapter that there were limited numbers of data categories in the diabetic
registry available to explain a substantial amount of variance in the proposed model. This
may be encouraging in terms of laying the groundwork for future research. More
comprehensive diabetic registries may be used in the future to determine cardiovascular
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risk factors and by doing so, would contribute valuable clinical information about how
cardiovascular disease and diabetes are related and launch innovations in improving
clinical care for patients with diabetes.
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